A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects

The study will consist of two parts: Subjects will be randomized to receive SHR-1707 as reflected by the guiding principle for the dose esclation/expansion phase. Each dose group includes a screening period, a baseline period, an observational period, and a safety follow-up period.

Inclusion criteria

• Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial,
• Male or female aged between 18 years and 45 years (inclusive) at the date of signed consent form in Part 1 and aged between 55 years and 80 years (inclusive) in Part 2
• Total body weight of 45~100 kg (inclusive), with a body mass index (BMI) of 19~32 kg/m2 (inclusive) at screening and baseline
• Subjects with good general health, no clinically significant abnormalities, or have underlying disease which is believed to have minimal impact on the study treatment in elderly subjects
• WOCBP agree to take effective contraceptive methods

Exclusion criteria

• Severe injuries or surgeries within 6 months before screening
• ALT, or AST or total bilirubin level <1.5x upper limit of normal range (ULN) at screening or baseline visits
• QTcF > 450msec (Male), QTcF > 470msec (Female) in 12-lead ECG test during screening and baseline
• Known history or suspected of being allergic to the study drug.
• Use of any medicine within 14 days (including any prescription, or over-the-counter medicine, herbal remedy or nutritional supplement, except for vitamins and acetaminophen with recommended dose [The dose of acetaminophen should be less than 2g/day, and no more than 3 days for continuous use]), or within 5 half-lives
• Live (attenuated) vaccination within 1 month before screening
• Blood donation or loss of more than 400 mL of blood within 3 months; or received blood transfusion within 3 months before screening.
• History of alcohol abuse in the past 12 months of screening
• History of illicit or prescription drug abuse or addiction within 12 months of screening
• More than 5 cigarettes daily for 12 months before screening
• Participation in clinical trials of other investigational drugs (include placebo) or medical devices within 3 months prior to screening
• Researchers and relevant staff of the research center or other persons directly involved in the implementation of the program